HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 05 & 06, May & June 2022 – Living Better for Longer: Cutting-Edge Research in Geriatric Medicine       » How Oxidation Can Lead to Mitochondrial Dysfunction and Age-Dependent Cognitive Disorders       » New Semiconductor Microchip Detects Prostate Cancer Markers With Ultra-High Sensitivity       » New Method for Synthesising Sulphur-Based Medicines Can Boost Drug Discovery Efficiency and Speed       » Selecting the Best Target for Deep Brain Stimulation in Parkinson’s Disease       » A Single Metabolite Can Promote Tissue Regeneration and Delay Ageing       » A New Light-Sensitive Way to Control Parathyroid Hormone Secretion for the Prevention of Bone Loss      
NEWS CRUNCH
ASLAN Pharmaceuticals announces first patient enrolled in global phase 2/3 study for varlitinib in gastric cancer
Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed across multiple indications including biliary tract, gastric, metastatic breast and metastatic colorectal cancers.

ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, announced the enrolment of the first patient in a global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients.

Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed across multiple indications including biliary tract, gastric, metastatic breast and metastatic colorectal cancers.

The global phase 2/3 study is a double blind, randomised two-arm study that aims to determine the efficacy of varlitinib in combination with mFOLFOX6 (a combination chemotherapy regimen) in comparison to mFOLFOX6 alone in the first-line setting. The first part of the study will enrol 40 HER1/HER2 coexpressing patients who were not exposed to prior systemic therapy and will read out in 2018.

Dr Bertil Lindmark, chief medical officer, ASLAN Pharmaceuticals, said: "This marks an important milestone for ASLAN as we treat the first patient in a further global late stage study of varlitinib, the second that we have initiated this year. Varlitinib has the potential to be an important first line therapeutic for metastatic or advance-stage gastric cancer patients who currently have very limited treatment options."

Gastric cancer currently ranks fourth in cancer incidence worldwide and is one of the most common types of cancer in Asia.

Varlitinib is also currently being investigated in a global pivotal trial in biliary tract cancer (BTC). Varlitinib has been awarded the Orphan Drug Designation (ODD) by the Korea MFDS for BTC. An ODD status was also granted by the US FDA for varlitinib in gastric cancer and cholangiocarcinoma.

Source: ASLAN Pharmaceuticals
NEWS CRUNCH  
news Medtec China 2022 Is Now Open for Visitor Registration, Helping Medical Device Manufacturers in Medtech Sourcing and Supply Chain Stabilisation
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy